Protease nexin-1 (PN-1) is a potent inhibitor of serine proteases, such as thrombin and plasminogen activators, which is secreted into the extracellular space. Since PN-1 is induced following lesion of the sciatic nerve, the effect of substances known to accumulate at the site of injury was examined in primary cultures of Schwann cells. Among the cytokines, growth factors, mitogens, neurotrophins, and neuroactive peptides analyzed, only angiotensin II (Ang II), calcitonin gene-related peptide (CGRP), and vasoactive intestinal peptide (VIP) were found to regulate the expression of PN-1 on Schwann cells. While Ang II and CGRP caused downregulation, VIP acted as a positive modulator of PN-1. Displacement of Ang II binding using the selective ligands losartan and CGP 42 112 led to a severalfold increase of PN-1 protein and mRNA over basal levels, indicating that the observed effect was mediated by specific binding sites. Indeed, the presence of AT, and AT, angiotensin receptor subtypes was demonstrated in cultured Schwann cells as well as in the rat sciatic nerve. Moreover, the detection of angiotensinogenand renin-mRNA in these cultures suggested an endogenous production of Ang II. This data identified one of the mechanisms regulating PN-1 synthesis. Altogether our results indicate that neuropeptides can differentially control the proteolytic activity of the microenvironment, providing new aspects of neuron-glia interactions in the intact tissue and following nerve injury.
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Cultured glial cells release a potent serine protease inhibitor with neurite-promoting activity (Monard et al., 1973; Guenther et al., 1985; Stone et al., 1987) . Following the determination of the amino acid sequence, this 43 kDa protein was named gliaderived nexin (GDN) (Gloor et al., 1986) . It was subsequently shown that GDN and protease nexin-1 (PN-l), a thrombin inhibitor released by cultured human skin fibroblasts, are identical Feb. 25, 1994; revised July 1, 1994; accepted July 13, 1994 (McGrogan et al., 1988) . As recent results demonstrate the presence of the inhibitor in a variety of cells, including neurons (Mansuy et al., 1993; Reinhard et al., 1994 ) the more general term protease nexin-1 is now used. The balance between proteases and protease inhibitors determines the proteolytic activity of the extracellular microenvironment, which may play an important role in cellular events such as migration, differentiation, and plasticity of neuronal cells (reviewed by Monard, 1988; Festoff et al., 1990; Pittman, 1990) .
Ischemia-induced lesions in the hippocampus and injection of 6-hydroxydopamine or excitotoxic agents (ibotenic acid, N-methyl-D-aspartate, and quisqualate) in the substantia nigra cause upregulation of PN-1 synthesis in astrocytes (Hoffmann et al., 1992; Scotti et al., 1994) . In the olfactory system, where constant degeneration and regeneration take place throughout life, PN-1 is constitutively expressed at high levels (Reinhard et al., 1988) . In the peripheral nervous system, injury of the rat sciatic nerve also triggers induction of PN-1 synthesis in a subpopulation of Schwann cells localized at the distal site of the injury (Meier et al., 1989) . As in vitro thrombin can cause the collapse of neurites (Gurwitz and Cunningham, 1988; Suidan et al., 1992) , and as PN-1 is the most potent endogenous thrombin inhibitor known today, the presence of PN-1 at sites of lesion suggests that it could protect remaining structures from prolonged and extensive proteolytic attacks. Alternatively, it remains to be seen if the neurite-promoting activity associated with PN-1 contributes in vivo to the permissive conditions supporting the regeneration of peripheral nerves or even to the abortive sprouting observed after lesion in the CNS. In any case, more knowledge about the molecular mechanisms regulating PN-1 synthesis is imperative.
In order to gain insight into the class of molecules involved in PN-1 regulation in glial cells, diverse injury-associated factors (reviewed by Fawcett and Keynes, 1990) were tested on Schwann cell cultures. Only treatment with the peptides angiotensin II (Ang II), calcitonin gene-related peptide (CGRP), and vasoactive intestinal peptide (VIP) affected PN-1 levels. In fact, these peptides have been shown to have a broad spectrum of physiological effects. In the nervous system, they may act as mitogens, neurotrophic factors, and/or neurotransmitters (for reviews see Laufer and Changeux, 1987; Gozes et al., 1989; Bunneman et al., 199 1; Dumoulin et al., 1992; Gressens et al., 1993) . Here we report that Ang II downregulates PN-1 expression in cultured Schwann cells, and that treatment with selective blockers of the angiotensin receptors causes a five-to eightfold increase in PN-1 expression over the basal level. Our results also provide support for an autocrine renin-angiotensin system in dissociated cell cultures derived from the sciatic nerve. Cultures ofSchwann cells. Primary Schwann cells were prepared essentially as described by Brockes et al. (1979) . Briefly, sciatic nerves from 3-to 4-d-old rats were enzymatically dissociated by incubation in Hank's salt solution (Ca2+, Mg 2 + free) containing 0.03% collagenase and 0.25% trvnsin (60 min. 37°C). After digestion, the supernatant was removed-and the nerves were triturated in Dulbecco's modified Eagle's medium (DMEM) and 10% fetal calf serum (FCS). The resulting singlecell suspension (l-l .4 x lo5 cells/nerve) was collected by centrifugation (500 x g, 10 min) and resuspended in pyruvate-free DMEM supplemented with 10% FCS (Sebak), penicillin G (100 U/ml), and streptomycin (100 pg/ml). Cells were plated on tissue culture dishes (Coming) coated with collagen (40 fig/ml PBS, Serva) at a density of 4 x lo6 cells per 60 mm dish. Cultures were kept in a 5% CO,/95% humidified air incubator at 37°C. To eliminate proliferating fibroblasts, cells were exposed to two treatments with the antimitotic agent cytosine arabinoside (1O-5 M): on day 1 (after plating) for 48 hr, and on day 4 for 24 hr. Except for the serum contained in the medium, no additional mitogen was added to the cells. All experiments were performed S-10 d after plating and with cultures containing at most 5% fibroblasts. Fibroblasts can clearly be distinguished from Schwann cells by the size and morphology of the nucleus visualized by Hoechst staining.
Cultures of jibroblasts. Fibroblasts were enriched by preplating the above prepared cell suspension for 30 min on polyomithine-coated dishes (0.5 mg/ml PBS). This method is based on the differential adhesion properties of tibroblasts and Schwann cells. The faster-adhering fibroblasts enriched in this way were passed 2-3 times during the next 8-10 d. The resulting cultures contained only l-3% Schwann cells.
Peritoneal macrophages. Macrophages were prepared and activated as described previously (Baichwa1 et al., 1988) . They were cultured in DMEM/lO% FCS at a density of l-2 x lo6 cells/cm2 and activated with lipopolysaccharide (LPS) (70 &ml), phorbol myristate acetate (PMA) (5 &ml), and ionomycin (100 nM), or CNS-myelin membrane fraction for 24 and 48 hr. The resulting conditioned media were used diluted 1: 1 in fresh DMEM/ 10% FCS. Media containing the various activating drugs or conditioned by nonactivated macrophages were used as controls.
Immunocytochemistry. PN-1 protein was detected in cultured cells using the monoclonal antibody 4B3. An alternative protocol was established for this purpose: cultures were fixed for 20 min with PBS containing 15% saturated picric acid and 4% paraformaldehyde. After being washed three times with PBS, fixed cells were permeabilized for 5 min with 0.2% Triton X-100 in PBS and then treated for 1 min with 0.4% SDS in 1.5 M Tris/HCl (pH 8.8). Following blocking (20 min in 0.2% Triton X-100/10% FCS), incubation with the primary antibody (1:500 dilution of ascites preparation in blocking solution) took place overnight at 4°C. After three washes with Triton-PBS, cells were incubated for 1 hr with FITC-conjugated secondary antibody (Jackson Immuno Research) diluted 1: 100 in blocking solution. The petri dish was finally washed three times with T&on-PBS and mounted in glycerin-PBS. All steps were carried out at room temperature unless otherwise indicated.
SDS-PAGE and immunoblotting. These steps were performed essentially as described by Reinhard et al. (1988) . Instead of rabbit polyclonal antibodies to PN-1, we used the monoclonal 4B3 (1: 1000 dilution of ascites preparation).
Drug treatment. Prior to drug addition and in order to remove traces of serum proteins, cells were washed twice with DMEM. The various agents were added to the cultures in serum-free DMEM supplemented with 5 fig/ml insulin, 5 &ml transferrin, 5 rig/ml sodium selenite, 16 &ml putrescine, 10 &ml progesterone, and 0.2 mg/ml stripped BSA as carrier. All treatments were based on single-drug administration, even for incubations longer than 24 hr.
Quantitation of secreted PN-1. A two-site enzyme-linked immunosorbent assay (ELISA) with a detection limit of 0.1 ng PN-1 per 100 ~1 conditioned medium was performed according to the method described by Meier et al. (1989) .
Northern blot analysis. Total RNA was extracted in a guanidium thiocyanate solution according to Chomczynski and Sacchi (1987) . The epineurium of sciatic nerves from PI4 and adult animals have been removed prior to RNA isolation. RNA samples were fractionated by electrophoresis on a 0.8% agarose-formaldehyde gel and capillary transferred to a nylon membrane (Boehringer) overnight in 10 x SSC. Staining of ribosomal RNA with 0.04% methylene blue solution confirmed the presence of equal amounts of RNA on all lanes. Hybridization of the membranes was performed as previously described by Mansuy et al. (1993) using lo6 cpm/ml of the various j>P-labeled probes. The rat PN-1 cDNA probe corresponds to a 1.3 kb XhoI-XbaI DNA fragment, the rat AT, probe to a PCR-generated 1.3 kb SmaI-SmaI fragment, and the rat PAI probe to a 726 bp PstI-ApaI fragment.
RT-PCR amplification and Southern blot analysis. Total RNA (2 pg) was reverse transcribed using a (dT)l, primer as described by Kawasaki (1990) . The primers used for the amplification of the rat AOGEN transcript were 5'-ACGCCCAGAACAACTTCTCCG-3' (nucleotides 1005-1025, sense) and 5'-CTACACAGGAGGCATCACACC-3' (nucleotides 1489-1509, antisense), and for renin, 5'-GCTCCCTGCAGTTGAT-CATGC-3' (nucleotides 935-945, sense) and 5'-GTCACTGGGTGA-CAGAGGAGC-3' (nucleotides 1242-l 262, antisense). The PCR was carried out as follows: five cycles of 1 min at 94°C 1 min at 55°C 2 min at 72°C. and 30 cvcles of 1 min at 94°C. 1 min at 60°C. 2 min at 72°C. The Taq DNA polymerase as well as the MMV-reversetranscriptase were purchased from Boehringer.
Samples of the reaction mix (15 ~1) were electrophoresed on 2% agarose gels, stained with ethidium bromide, and further treated for Southern blot analysis according to standard procedures (Maniatis et al., 1987) , using lo6 cpm/ml of the various '*P-labeled probes. The rat AOGENcDNA probe corresponds to a 1.3 kb StuI/NCOI fragment and the rat renin probe to a 1.3 kb HindIII/BamHI fragment.
Membrane preparation and Ang II binding assays. These were performed as described by Whitebread et al. (1989) . Briefly, cells were washed with PBS and harvested using a rubber policeman. After homogenization in 20 mM sodium bicarbonate with a Polytron and centrifueation at 60.000 x B for 30 min. the pellet was resuspended in 50 mM Tris-HCI buffer, pH-7.4, containing 125 mM NaCl, 6.5 mM MgCl,, 1 mM EDTA, and 2 mg'ml BSA. Finally, a cocktail of peptidase inhibitors (phosphoramidon, leupeptin, antipain, and bestatin, each at 1.25 &ml) was added. The membrane preparation was kept in ahquots at -80°C until used.
Binding assays consisted of competition experiments, which were performed using 12SI-Ang II and increasing amounts of unlabeled Ang II, losartan, or CGP 42 112. In a total reaction volume of 250 ~1, 20-60 mg membrane protein was incubated with 175 PM labeled Ang II * unlabeled competitors for 1 hr at 25°C. The reaction was terminated by adding ice-cold PBS. Free and bound 1251-Ang II were separated by filtration through Whatman GF/F filters, which were washed twice with 4 ml ice-cold PBS. The bound fraction, trapped on the filter paper, was counted in a y-counter (Pharmacia). Binding constants were calculated from the competition curves using the program LIGAND.
Results
Immunocytochemistry and immunoblot analysis of cultures derived from dissociated sciatic nerves confirmed previous data (Meier et al., 1989) , suggesting that Schwann cells are the main source of PN-1 in the peripheral nervous system. Staining per- (Fig. MC) . In contrast to the in vivo studies, all these cells were both PN-1 and SlOO positive (data not shown). Occasional fibroblasts (3-5%), easily identified by their large nucleus, showed weak staining ( Fig. lC,D) . Immunoblot analysis confirmed these observations: while Schwann cell cultures synthesized high amounts of PN-1, only trace levels were found in cultures containing 97% of fibroblasts (Fig. 1E) . Using a sensitive ELISA assay, agents capable of modulating PN-1 synthesis were screened in primary cultures of Schwann cells. Potential candidates were substances known to be secreted by macrophages or to be regulated following nerve lesion (for reviews see Nathan, 1987; Fawcett and Keynes, 1990) , including cytokines, mitogens, growth factors, and neurotrophic factors ( Table 1) . None of them influenced PN-1 synthesis with the exception of NGF, which caused a decrease in PN-1 mRNA levels after 9 hr of treatment (data not shown). However, a marked effect was obtained only at high concentrations of NGF (above 100 @ml) and could not be blocked by antiserum against NGF (Harlan Bioproducts For Science, Indianapolis, IN). In view of these facts, the presence of a contaminant could not be excluded. Since renin-like activity has been found in some NGF preparations (Otten et al., 198 l) , we investigated whether renin itself was responsible for the decrease in PN-1 mRNA levels.
Incubation of Schwann cell cultures with 50 r&ml of recombinant renin showed that PN-1 expression is transiently downregulated in a time-dependent manner (Fig. 2) . A decrease of 23-26% was observed within the first 6-7 hr of treatment. The maximal effect was reached at 9 hr of incubation (97% of reduction), and after this time point, PN-1 mRNA slowly increased, returning to basal levels after 24 hr of renin application. It has been recently shown that a rapid decrease in Ang II receptor density (90% within 30 min) takes place via receptor internalization following incubation of neuroblastoma cells with Ang II (Reagan et al., 1993) . This process of desensitization could thus explain why the effect caused by renin on PN-1 expression is observed only within a narrow time window.
Since the physiological role of renin is to initiate the production of the peptide hormone Ang II, the specificity of our initial observation was further examined by testing the effect of Ang II and Ang II antagonists in the regulation of PN-1 expression.
The renin-angiotensin system and its involvement in PN-1 regulation The effector molecule of the renin-angiotensin system is the octapeptide Ang II, which originates from two successive proteolytic cleavages of the precursor protein angiotensinogen (AOGEN) by renin and the angiotensin-converting enzyme (ACE). Ang II mediates its effects through specific receptors Afier a culturing period of 8-10 d, primary Schwann cells were incubated for 24 and 48 hr with the various agents under serum-free conditions, with exception of the macrophage-conditioned media containing serum. The concentrations used were chosen within the physiological range or according to the literature. Following these treatments, carried out in triplicate, the amounts of PN-I secreted into the media were quantified by ELISA and normalized to the total amount of protein determined by the Bio-Rad assay. During the period of incubation, none of the various compounds showed toxic effects or induced significant changes in the morphology of the cells. IL-I, interleukin-I; GGF, glial growth factor; LPS, lipopoiysaccharide; PMA, phorbol myristate acetate; PDGF, platelet-derived growth factor; FGF, tibroblast growth factor; TGF & transforming growth factor 8; EGF, epidermal growth factor, NGF, nerve growth factor, NT-3, neurotrophin-3; BDNF, brain-derived neurotrophic factor; CNTF, ciliary neurotrophic factor; ANP, atria1 natriuretic peptide; CCK, cholecystokinin.
located on the cell surface. Selective synthetic ligands are available for both Ang II receptor subtypes. Losartan (formerly DuP 753) binds to the subtype AT,, and CGP 42112 and PD 123319 to AT, (reviewed by de . The use of these compounds allows a selective displacement of Ang II as well as the discrimination of the receptor subtypes involved.
of PN-1 protein secreted into the culture medium were measured after 9 and 24 hr of treatment. Changes were apparent within 9 hr (data not shown), but the response after 24 hr was more remarkable (Fig. 3B) . The delay between the maximal effect measured at the mRNA and protein level could be explained by the high stability of the PN-1 transcript (half-life of 8-10 hr in Schwann cells, data not shown), and/or by the stability of the protein in the conditioned medium. However, the changes detected in mRNA levels were consistently reflected in the amounts of synthesized and secreted protein. Ang II can mimic the downregulation of PN-1 expression caused by renin, although less efficiently (Fig. 3AJ ). This could be explained by the high instability of this peptide. Indeed, about 70% of the Ang II added to the cultures was found to be degraded within the first 9 hr of incubation (data not shown). As expected, when the ACE inhibitor enalapril was added together with renin, PN-1 levels remained unchanged. Interestingly, preincubation of the cultures with either of the receptor ligands, losartan or CGP 42 112, prior to Ang II addition not only prevented the decrease of PN-1 but triggered a severalfold upregulation over basal levels (Fig. 3A,B) . The same effect was observed following treatment with losartan, CGP 42112, or PD 1233 19 alone, without subsequent administration of Ang II (data not shown). The large upregulation of PN-1 caused by these compounds could be due to the inhibition ofactive Ang II present in the cultures; evidence supporting an endogenous production ofAng II will be presented below. A permanent receptor occupancy by endogenously produced Ang II may lead to constitutive low production of PN-1; receptor blockade may completely derepress the system, which then reaches much higher levels than basal. On the basis of this cascade, it was expected that Ang II would Dose-response studies using losartan and CGP 42112 (Fig.  repress PN-1 expression, and that ACE inhibitors as well as 3C9 showed PN-1 increase even at very low concentrations (lo-* angiotensin antagonists may reverse the effect, which indeed M for losartan; lo-lo M for CGP 42 112). This would exclude proved to be the case. RNA samples were collected 9 hr after the possibility of nonspecific cross-binding and support the idea treatment with the various compounds (Fig. 3A) . The amounts of a mechanism potentially mediated by both AT, and AT, Northern blot analysis was performed using 5 pg of total RNA extracted from these cultures. The autoradiogram was quantified by measuring the optical density at 400 nm using a Dual-wavelength TLC Scanner (Shimadzu). The obtained values, which were normalized taking the signal at zero time as 100% intensity, were 74% (after 3 hr), 77% (after 7.5 hr), 3% (after 9 hr), 31% (after 12 hr), 59% (after 16 hr), and 79% (after 24 hr). Arrowheads indicate the position of the ribosomal RNAs, which were detected by methylene blue staining, as shown on the bottom. In lanes 5 and 6, the receptor ligands were added 10 min before Ang II (1 PM). Arrowheads indicate the position of the ribosomal RNAs (methylene blue staining shown on the bottom). B, Amounts of PN-1 protein secreted during 24 hr by cultures treated as in A. Conditioned media were collected and the amount of secreted PN-1 was analyzed by ELISA. The values shown represent averages from three parallel dishes f SD. C, Dose-response analysis with the selective ligands, losartan and CGP 42 112, which bind to AT, and AT, receptors, respectively. As described above, cultures were incubated for 10 min with one or the other compound, followed by addition of Ang II (1 PM). Changes in the amounts of secreted PN-1 after a 24 hr treatment were analyzed by ELISA. c, control levels of untreated cells. The illustrated values represent averages of three dishes k SD.
receptor subtypes. Although CGP 42 112 caused effects analowith the AT,-cDNA (Buisson et al., 1992; Brechler et al., 1993 ; gous to those of losartan in PN-1 expression, it remained to be Kambayashi et al., 1993) . To clarify this aspect, we treated determined whether in our system the peptide CGP 42 112 was Schwann cell cultures with the nonpeptidic AT, antagonist PD acting as an AT, antagonist or as an agonist, as described for 
Detection and characterization of Ang II receptors in Schwann cells
While specific angiotensin receptors were found on neuronal cells and astrocytes (reviewed by Sumners et al., 1990 ) their presence had not yet been reported on Schwann cells. We performed Northern blot analysis using the AT,-cDNA probe (Fig.   4A ). For this purpose, total RNA was isolated from cultured Schwann cells as well as from fresh undissociated rat sciatic nerves at various developmental stages. Since the AT, receptor subtype is highly expressed by aortic vascular smooth muscle cells (Whitebread et al., 1989) their RNA was used as positive control. The band detected on the autoradiogram corresponds to the 2.3 kb transcript previously described by Murphy et al. (199 1) . Expression of the AT,-mRNA in Schwann cells is drastically reduced during increasing time in culture (O-8 d) . In fact, to clearly detect the transcript in cells cultured for 3 and 8 d, we had to perform Northern blot analysis with up to 80 pg of total RNA per lane. AT, -mRNA was present in the sciatic nerve in vivo at various developmental stages (postnatal day 3, 14, and adult) (Fig. 4A) .
A further characterization of Ang II receptors was undertaken by Ang II binding studies. The following assays were performed using membrane fractions prepared from Schwann cells kept in culture for a short period of time: cells were allowed to recover from the enzymatic dissociation and harvested 20-24 hr after plating, when AT, receptor expression was expected to be the highest, according to the results shown in Figure 4A . Since such assays require a high number of primary Schwann cells, the curves shown in Figure 4B illustrate single measurements; however, similar values were obtained with other membrane preparations tested in independent experiments. Competition curves with unlabeled Ang II were used to estimate the binding constants: total concentration of binding sites (B,,,) = 79.2 fmol/ mg protein and the dissociation constant (&) = 0.75 nM (means of two determinations). These values are comparable to those described for neuronal and astrocytic cultures (Sumners et al., 1990) . In addition, no detectable receptor levels were found using membrane fractions of fibroblast-enriched cultures (data not shown). Incubation with the ligand Ang (l-6) showed no binding displacement (data not shown), indicating an absence of mycoplasma contamination, a potential source of Ang II receptors in cell cultures (Whitebread et al., 1993) . The proportions of Ang II receptor subtypes were 17% AT, and 83% AT, (means of two determinations), as estimated from the competition curves of losartan (AT, selective) and CGP 42 112 (AT, selective). It thus appears that AT, represents the majority of the angiotensin receptors present on freshly plated Schwann cells. However, it must be borne in mind that this ratio could change during time in culture, as reported for other cell types (reviewed by de Gasparo et al., 1992) . Binding assays performed with sciatic nerve membranes of P14 and adult animals confirmed the presence of both receptor subtypes also in vivo. The ratio AT,/AT, consisted of about 45/55 and 90/10, respectively (data not shown), indicating notable changes in the expression of both receptor subtypes during development, as previously described in other tissues (Tsutsumi and Saavedra, 1991a) .
Evidence for Ang II production in Schwann cell cultures
The information about the production of components of the renin-angiotensin system in cells of the nervous system is fragmentary, mainly because the amounts synthesized are extremely low compared to liver, kidney, or blood, and thus require more sensitive detection methods. In addition, the existence of alternative enzymatic pathways has been recently postulated (reviewed by Ferrario et al., 1990) . However, transcripts of the precursor protein and of various enzymes potentially involved in Ang II generation are widespread in the brain (reviewed by Bunnemann et al., 199 1) .
The presence of Ang II in the serum-free conditioned medium of Schwann cells has been measured according to the radioimmunoassay described by Nussberger and colleagues (1985) but omitting the HPLC purification. Interestingly, although small amounts of Ang II were released by these cultures (4.22 f 0.24 fmol/ml, n = 3) 29-fold higher levels were detected following incubation with renin for 9 hr (125 fmol/ml) (data not shown). Moreover, these preliminary results also show that the Ang II production by Schwann cell cultures was stimulated in a timedependent manner upon renin treatment, becoming less pronounced after 16 or 24 hr (57 and 49 fmol/ml, respectively) (data not shown). It is worth noticing that the same 9 hr of incubation are required to obtain the maximal inhibition of PN-1 mRNA expression. Since high amounts of AOGEN and prorenin are, however, present in the serum-containing cultures previous to the change to serum-free conditions, the existence of an endogenous renin-angiotensin system had to be confirmed using another strategy. We therefore tested whether the mRNA transcripts of AOGEN and renin, the only proteins exclusively involved in the production of Ang II, are present in Schwann cell cultures. For this purpose, RT-PCR was performed, taking as positive controls liver and kidney, the main sources of AOGEN and renin, respectively. The results are summarized in Figure  5 . The size of the RT-PCR products obtained corresponds to the expected fragments, namely, 504 bp for AOGEN (Fig. 54) and 337 bp for renin (Fig. 5B) ; their identity was confirmed by Southern blot analysis using the corresponding rat AOGENand renin-cDNA probes (Fig. 5A,B) . Further experiments using primers selected to amplify another region of the AOGEN-or renin-cDNA showed a single specific product as well (data not shown). Similar results have been obtained by RT-PCR performed with RNA extracted from fibroblast-enriched cultures and the schwannoma cell line P,T (data not shown). Therefore, and since'the PCR can amplify even single molecules of mRNA transcript, it remains to be determined whether Schwann cells, fibroblasts, or both cell types produce Ang II in these primary cultures. However, since Schwann cells and fibroblasts are also in close contact in vivo, our results support the possibility of an endogenous renin-angiotensin system acting in an autocrine and/ or paracrine manner.
Cell type-spec$c regulation of protease inhibitors by Ang II Olson and colleagues (199 1) have recently shown that treatment of cultured astrocytes with Ang II increases the secretion of the protease inhibitor plasminogen activator inhibitor-1 (PAI-1) and of a tissue metalloprotease inhibitor-related protein (hTIMP) in a coordinated way. Since the opposite regulatory pattern is found for PN-1 in Schwann cells, we investigated how PAI-1, as another example of a protease inhibitor, would be affected by Ang II in these cells. Northern blot analysis showed that PAI-mRNA levels are regulated in Schwann cells in a fashion similar to that of PN-1: while renin and Ang II repressed expression, Ang II antagonists induced it (Fig. 6) . The two mRNA bands detected on the autoradiogram correspond to the 2.4 and 3.4 kb PAI-transcripts previously described by Lund et al. (1987) . Ang II did not significantly influence PN-1 expression when added to astrocytic cultures prepared from neonatal rats (data not shown). PAI-secretion was also found to be affected only in cultured astrocytes derived from 2 1 -d-old rats (Olson et al., 199 1) . Further investigation should define the regulatory effect of Ang II on PN-1 synthesis in such cultures. In summary, this data indicates that Ang II regulates the expression of various protease inhibitors in a coordinated way but in a cell type-specific manner. An opposite regulation in different cell types has in fact already been shown following injury of the blood vessel wall, where Ang II decreases the secretion of the protease u-PA in endothelial cells but increases it in smooth muscle cells (Bell and Madri, 1990 ).
Effect of other neuroactive peptides on PN-1 expression
In addition to Ang II, among the peptides tested (see Table I ), only CGRP and VIP affected PN-1 expression (Fig. 7) . While CGRP repressed mRNA and protein levels, VIP acted as a positive regulator of PN-1 synthesis. This finding is in fact in agreement with previous observations of Brenneman and coworkers (1987) to obtain a maximal effect (24 hr at the mRNA and 36 hr at the protein level) (Fig. 7) .
Discussion
The present study shows that Ang II, CGRP, and VIP differentially modulate the synthesis of PN-1 in cultured Schwann cells, indicating that changes triggered by neuropeptides could result in a local modulation of the extracellular proteolytic activity. None of a large number of injury-associated factors was able to regulate PN-1 expression in primary Schwann cell cultures. It is particularly surprising that IL-l remained without effect in view of it having been reported to upregulate the expression of PN-1 in cultured skin fibroblasts and the SK-N-SH neural cell line (Guttridge et al., 1993; Vaughan and Cunningham, 1993) . It is, however, worth mentioning that IL-1 induced the synthesis of NGF in the sciatic nerve Lindholm et al., 1987) but failed to do so in Schwann cell cultures (Matsuoka et al., 199 1) . Furthermore, TGF@ and PDGF, which cause increased PN-1 synthesis in these SK-N-SH cells (Vaughan and Cunningham, 1993) , did not influence it in cultured Schwann cells. It seems, therefore, that the mechanisms regulating PN-1 expression differ markedly among the various cell types, as has been previously described for NGF. The upregulation of NGF in fibroblasts is mediated by IL-l, but in the case of Schwann cells, by drugs like forskolin which raise intracellular levels of CAMP (Matsuoka et al., 1991) . It was worth noticing as well that TGFfi treatment did not influence PN-1 synthesis, since it has recently been described as enhancing the secretion of PAI-1 by cultured adult rat Schwann cells (Rogister et al., 1993) ; however, this result is not too surprising as PN-1 and PAI-1 were shown to have different expression pattern (Sappin0 et al., 1993) . An important event during peripheral nerve regeneration is the activation of Schwann cell proliferation, which reaches the highest rate within 3-5 d (Pellegrino et al., 1986) . As the maximal induction of PN-1 takes place only shortly thereafter, namely 6-7 d following nerve injury (Meier et al., 1989) it is interesting to note that agents mitogenic for Schwann cells do not influence the levels of PN-1 synthesized, at least under the culture conditions used here.
An endogenous renin-angiotensin system regulates PN-1 expression in cultured Schwann cells Treatment of Schwann cell cultures with renin or Ang II represses PN-1 mRNA and protein levels. This downregulation can be specifically reversed by Ang II antagonists in a dosedependent manner. At this stage, we do not know whether the effects observed result from changes in transcription rate or in the stability of PN-1 mRNA. However, the correlation we find between the amount of PN-1 mRNA and protein suggests that modifications in the efficiency of translation are unlikely to be a major mechanism in PN-1 regulation. In addition, Ang II, endogenously produced by these cell cultures, may regulate PN-1 synthesis in an autocrine-paracrine way. Moreover, this endogenous renin-angiotensin system appears to similarly affect the expression of PAI-1, another protease inhibitor.
Our results indicate that the basal level of PN-1 in untreated cells may reflect a semirepressed state, resulting from a constitutive but partial occupancy of Ang II receptors. The addition of Ang II may then lead to activation of all the receptors and therefore to maximal repression of PN-1 synthesis. On the other hand, maximal production of PN-1 was reached following Ang II displacement using losartan, CGP 42112, or PD 1233 19. Interestingly, blocking only one receptor subtype was enough to obtain maximal PN-1 derepression. A simultaneous activation of AT, and AT, receptors might thus be required for the repression of PN-1. This would suggest that both receptor subtypes trigger distinct but ultimately converging intracellular pathways, the activation of only one of them being insufficient. Indeed, previous studies support the idea that some cellular responses triggered by Ang II may be simultaneously mediated by both receptor subtypes and that a balance in their regulation may exist Zarahn et al., 1992) . Since astrocytes contain only AT, and Schwann cells both receptor subtypes, an unequal receptor composition could possibly account for the differential effects caused by Ang II on the PAIexpression in these two types of cells. Obviously, potential interactions between both receptor subtypes should be further investigated.
Possible role of Ang II receptors in Schwann cells
The existence of AT, and AT, receptor subtypes on Schwann cells is demonstrated here for the first time by Northern blot analysis and Ang II binding studies. Three main pieces of evidence suggest that the described Ang II binding sites are likely to be physiological receptors for Ang II. First, the measured binding of lZSI-Ang II to the membrane preparation was saturable and of high affinity (Kd = 0.75 nM). Second, the effect of Ang II on intact cells was specifically blocked in a dose-dependent manner by selective ligands. Third, the receptors were found not only in cultured cells, but also in fresh biopsy of rat sciatic nerve, where the ratio AT,/AT, showed strong differences between young and adult animals. In the brain, maximal AT, levels were found during embryonic and early postnatal stages. It has been postulated, therefore, to be involved in various developmental processes (Tsutsumi and Saavedra, 199 la; Mukoyama et al., 1993) . The expression ofAT, receptors was shown to be strongly regulated also during differentiation of neuro-. blastoma cells and wound healing (reviewed by Tallant et al., 199 1; de Gasparo et al., 1992) . Finally, the presence on Schwann cells of more than one receptor subtype would support the possibility of distinct intracellular changes in response to Ang II. In this context, whether the ratio of AT,/AT, plays a role in the way Ang II modulates PN-1 expression remains to be investigated. It also remains to be seen if the downregulation of Ang II receptors observed here with time in culture could have some physiological relevance for the regulation of PN-1 in viva These results indicate that it is possible that other types of receptors could also be downregulated with time in culture. It is therefore not excluded that one or the other of the injuryassociated substances could have influenced PN-1 synthesis if tested at different stages of the culture.
Neuropeptides as mediators of neuron-glia interactions Many neuropeptides are considered to mediate diverse interactions between neurons and glial cells (Gazes and Brenneman, 1989; Bunneman et al., 199 1; Dumoulin et al., 1992) . However, the mode of action of Ang II, CGRP, and VIP in the nervous system is poorly understood. The studies aimed to characterize their neurotrophic properties indicate that the responses induced in neuronal cells require the presence of glial cells (Brenneman et al., 1987; Iwasaki et al., 199 1) . Indeed, functional binding sites for a variety of neuroactive peptides including VIP, calcitonin, somatostatin, and substance P have been described on astrocytes and Schwann cells (for reviews see Villegas et al., 1988; Wilkin and Cholewinski, 1988) . Together with the studies mentioned previously (Brenneman et al., 1987; Bell and Madri, 1990; Olson et al., 199 l) , our results confirm and point out the high diversity in the potential of neuropeptides to modulate the proteolytic activity in the microenvironment by regulating the amounts of secreted proteases and protease inhibitors.
Numerous studies have shown that the expression of various neuropeptides, including VIP and CGRP, is modulated following axotomy of the sciatic nerve. While VIP levels are increased in sensory and motor neurons (Shehab and Atkinson, 1986; Villar et al., 1989; Doughty et al., 1991) CGRP levels are differentially regulated in these distinct neuronal populations. CGRP immunoreactivity is increased in motoneurons but it is decreased in sensory neurons of the dorsal root ganglia (Noguchi et al., 1990; Doughty et al., 199 1; Dumoulin et al., 1992) . Sensory fibers are most likely responsible for 95% of the axonally transported CGRP in the intact sciatic nerve, and, in fact, the anterograde axonal transport of CGRP decreases to 40-50% of control values 6-8 d after lesion . It is therefore plausible that the lesser amounts of CGRP synthesized by sensory neurons may lead to a lower level of the peptide in the injured nerve. Whether a direct relationship exists between these mechanisms and the induction of PN-1 observed after injury (Meier et al., 1989) remains to be investigated. Furthermore, neither the regulation of Ang II nor the regulation of Ang II receptors following nerve lesion is yet known.
Our data are, nevertheless, consistent with the idea that neuropeptides produced by neuronal cells may cause modulation of PN-1 secretion by Schwann cells. For instance, it is conceivable that peptides such as Ang II and CGRP released by intact neurons would strongly downregulate PN-1 synthesis and that nerve injury would interrupt this negative control, allowing Schwann cells to react by default by the production of PN-1. By contrast, increased amounts of secreted VIP following lesion could enhance this effect. Alternatively, neurons could repress PN-1 synthesis by releasing molecules able to modulate the levels of endogenous Ang II and Ang II receptors in surrounding non-neuronal cells. Obviously, further detailed in vivo studies will be required to establish the physiological relevance of the neuropeptide-mediated regulation of PN-1 synthesis following nerve lesion.
